CSIMarket Company Name, Ticker, Suppliers, else..
 
Context Therapeutics Inc   (NASDAQ: CNTX)
Other Ticker:  
 
 
Price: $1.0100 $0.03 3.230%
Day's High: $1.05 Week Perf: -1.94 %
Day's Low: $ 0.93 30 Day Perf: -25.74 %
Volume (M): 260 52 Wk High: $ 2.75
Volume (M$): $ 263 52 Wk Avg: $1.71
Open: $0.98 52 Wk Low: $0.89



 Market Capitalization (Millions $) 81
 Shares Outstanding (Millions) 80
 Employees 13
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) 63
 Capital Exp. (TTM) (Millions $) 0

Context Therapeutics Inc
Context Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative cancer treatments. The company focuses on discovering and developing drugs that target the estrogen receptor (ER) pathway in breast and other hormone-driven cancers. Their research aims to address unmet medical needs and improve patient outcomes in the field of oncology. Context Therapeutics Inc utilizes a multidisciplinary approach to drug discovery, combining cutting-edge science, computational biology, and precision medicine to identify and advance novel therapies.


   Company Address: 2001 Market Street, Philadelphia, 19103 PA
   Company Phone Number: 225-7416   Stock Exchange / Ticker: NASDAQ CNTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        1.68% 
CARM        0.62% 
CELU        11.11% 
INBP        16.89% 
KZR   -1.75%    
MRUS   -2.47%    
• View Complete Report
   



Management Changes

Context Therapeutics: Bridging Challenges with Innovation in the Fight Against Cancer,

Published Mon, Jan 13 2025 12:30 PM UTC

The Evolution of Cancer Treatment: Context Therapeutics Enters a New Era with Strategic Leadership and Innovative TherapiesIn an era where the quest for effective cancer treatments is both urgent and dynamic, Context Therapeutics Inc. is making significant strides toward becoming a key player in the biopharmaceutical landscape. Recent leadership appointments and upcoming pr...
Product Service News

Advancing Cancer Treatment Context Therapeutics to Showcase CTIM-76 at SITC 2024

Published Wed, Oct 16 2024 11:30 AM UTC

Abstract: Context Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies for solid tumors, has announced the presentation of a poster highlighting its clinical asset, CTIM-76. This bispecific antibody targeting Claudin 6 and CD3 will be featured at the Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting, which will occur from ...
Contract

BioAtla and Context Therapeutics Forge Exclusive License Agreement to Advance BA3362, a Pioneering Nectin-4 x C...

Published Mon, Sep 23 2024 11:31 AM UTC

Context to obtain exclusive development and commercialization rights to BA3362

In a significant move within the biopharmaceutical industry, BioAtla, a global clinical-stage biotechnology company, and Context Therapeutics, a biopharmaceutical company focused on novel treatments for cancer, have announced an exclusive worldwide license agreement for the deve...
Clinical Study

Innovative Therapeutics and Leadership Appointments Propel Context Therapeutics Forward in Oncology Resea...

Published Thu, Aug 1 2024 11:30 AM UTC

Context Therapeutics Inc., a pioneering company in the development of novel cancer therapies, has made a significant formal announcement regarding its leadership and clinical strategy. The recent appointments of Dr. Claudio Dansky Ullmann as Chief Medical Officer (CMO) and Ms. Karen Andreas as Vice President (VP) of Clinical Operations mark a pivotal step for the company?s m...
Clinical Study

Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95 In a move that carries...

Published Wed, Jul 10 2024 11:30 AM UTC

Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95 In a move that carries promising implications for cancer therapy, Context Therapeutics has announced the acquisition of a Phase 1-ready bispecific antibody, CT-95. CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody, is designed to harness the patient?s own immune system to target and e...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com